ChromaDex (NASDAQ:CDXC) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of ChromaDex (NASDAQ:CDXC) in a research note released on Monday morning,Benzinga reports. HC Wainwright currently has a $11.00 price objective on the stock.

Other analysts also recently issued research reports about the company. StockNews.com downgraded ChromaDex from a “strong-buy” rating to a “buy” rating in a research note on Thursday, March 6th. LADENBURG THALM/SH SH upped their target price on ChromaDex from $6.80 to $8.10 and gave the company a “buy” rating in a research report on Wednesday, March 5th.

ChromaDex Price Performance

Shares of CDXC opened at $7.87 on Monday. The company’s fifty day moving average price is $6.16 and its 200-day moving average price is $5.44. ChromaDex has a 1-year low of $2.31 and a 1-year high of $9.18. The firm has a market capitalization of $611.50 million, a PE ratio of 787.29 and a beta of 2.21.

Institutional Investors Weigh In On ChromaDex

Several hedge funds have recently modified their holdings of the company. Squarepoint Ops LLC purchased a new position in ChromaDex during the fourth quarter worth approximately $555,000. Two Sigma Investments LP acquired a new position in shares of ChromaDex during the 4th quarter worth approximately $675,000. State of Wyoming purchased a new position in shares of ChromaDex during the 4th quarter valued at approximately $39,000. Sherbrooke Park Advisers LLC acquired a new stake in ChromaDex in the 4th quarter valued at $94,000. Finally, ProShare Advisors LLC purchased a new stake in ChromaDex in the 4th quarter worth $74,000. 15.41% of the stock is owned by hedge funds and other institutional investors.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.